Skip to content

A Clinical study on Tamra Sindura in the management of Psoriasis

Pharmaceutico- analytical study of tamra sindura and its Clinical efficacy in the management of kitibha kushta (psoriasis) - nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069506
Enrollment
30
Registered
2024-06-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere Health Condition 2: L988- Other specified disorders of the skin and subcutaneous tissue

Interventions

Intervention1: Tamra Sindura: 125 mg BD Oral 60 days Intervention2: Tamra Sindura: 125 mg bd once a day for 60 days Control Intervention1: not applicable: not applicable

Sponsors

Dr B Bhaskara Rao
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Known cases of Psoriasis, without psoriatic arthropathy Exhibiting psoriatic triad – Bright pink or red lesions with pronounced edges, covered with silvery white scales, the scales can be easily separated from the lesion Under the scales there appears a pinkish moist tender skin With the scarping of the moist skin there appear tiny blood droplets (Auspitz’s sign) 2.Patients suffering from mild to moderate Psoriasis with less than 50 % of the body surface involvement 3.Patients having less than 10 years duration 4.Positive histo - pathological finding.(Skin-biopsy - optional)

Exclusion criteria

Exclusion criteria: 1.Age below 18 years and above 60 years 2.Patients with other forms of Psoriasis like Guttate/ Pustular/ Erythrodermic/ inverse. 3.Patients suffering from severe Psoriasis with more than 50% of the body surface involvement 4.Patients having chronic disease i.e. more than10 years duration 5.Patients who cannot report in person every 2 weeks in the OPD 6.Patients with poorly controlled Hypertension ( >160/100 mmHg) 7.Patients with poorly controlled Diabetes Mellitus having Hb A1C of > 7.5% 8.Patients on medication with corticosteroids, phototherapy, biologics, antidepressants any other drugs that may have an influence on the outcome of the study. 9.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 10.Symptomatic patient with clinical evidence of Heart failure. 11.Known HIV positive cases

Design outcomes

Primary

MeasureTime frame
Relief of dryness hardness itching roughness hyper pigmentationTimepoint: 15 days

Secondary

MeasureTime frame
As per scoring & grading for assessmentTimepoint: Treatment period of 60 days Assessment for every 15 days with active Follow up of 3 months

Countries

India

Contacts

Public ContactDr B Bhaskara Rao

Dr N R S Government Ayurvedic College Vijayawada A P

dr.skovi@gmail.com9491925109

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026